Dual-targeted CAR-NK cell therapy: optimized CAR design to prevent antigen escape and elicit a deep and durable response in multiple myeloma

被引：2
|
作者：
Yang, Cuiqing
Wang, Yifang
Liu, Tingting
Wang, Chao
Wang, Huanyu
Wang, Qingyang
Wang, Qin
Ye, Gang
Tang, Renhong
Cao, Zhuoxiao
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-4077
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4077
引用
收藏
页数：2
相关论文
共 24 条
  • [21] KarMMa Subanalysis: Correlation of Baseline Characteristics with Complete Response (CR) to Idecabtagene vicleucel (Ide-Cel, bb2121), a BCMA-Targeted CAR-T Cell Therapy, in Patients with Relapsed and Refractory Multiple Myeloma (RRMM)
    Einsele, H.
    Shah, N.
    Munshi, N.
    Berdeja, J.
    Jagannath, S.
    Finney, O.
    Martin, N.
    Agarwal, A.
    Rowe, E.
    Campbell, T. B.
    San-Miguel, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 248 - 248
  • [22] BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor ( CAR) T-Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 Study
    Bal, Susan
    Htut, Myo
    Nadeem, Omar
    Larry, Anderson D., Jr.
    Kocoglu, Hakan
    Gregory, Tara
    Rossi, Adriana C.
    Martin, Tom
    Egan, Daniel N.
    Costa, Luciano
    Hu, Hongxiang
    Chen, Yanping
    Li, Shaoyi
    Kelly, Lisa M.
    Sarkis, Naomey
    Ziyad, Safiyyah
    Kao, Wei-Ming
    Kaeding, Allison June
    Burgess, Michael R.
    Berdeja, Jesus G.
    BLOOD, 2023, 142
  • [23] The B Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor (CAR) T Cell Therapy Idecabtagene Vicleucel (Ide-Cel; Bb2121) in Relapsed and Refractory Multiple Myeloma (Rrmm): Outcomes from a Phase 1 Study Support the Phase 3 Karmma-3 Study Design to Compare IDE-Cel Versus Standard Triplet Regimens
    Einsele, Hermann
    Raab, Marc
    Kroeger, Nicolaus
    Fenk, Roland
    Scheid, Christoph
    Munshi, Nikhil
    Petrocca, Fabio
    Hege, Kristen
    Novick, Steven
    Raje, Noopur
    Kochenderfer, James
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 213 - 213
  • [24] Clinical Activity of BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma (MM): First Results from a Phase 1, Multicenter, Open-Label Study
    Bal, Susan
    Kocoglu, M. Hakan
    Nadeem, Omar
    Htut, Myo
    Gregory, Tara
    Anderson, Larry D., Jr.
    Costa, Luciano J.
    Buchholz, Tonia J.
    Ziyad, Safiyyah
    Li, Meng
    Chen, Yanping
    Kaeding, Allison J.
    Burgess, Michael R.
    Hege, Kristen
    Berdeja, Jesus
    BLOOD, 2022, 140
123